Abstract
This paper will briefly review the current situation in the treatment of advanced breast cancer. Historically hormonotherapy was the first modality, which was used in the therapy of this disease. In an unselected population the results of endocrine treatment have remained stable in the last three decades: about 30$ of the patients will achieve a partial remission, which will last between 10–20 months. In the last 10 years combination chemotherapy became the most widely applied treatment modality for advanced breast cancer. However nowadays it has been realised, that combination chemotherapy can only be palliative, whereas a few years ago it was hoped that with this treament at least some patients could be cured. With an optimal combination chemotherapy 50–70$ of the patients will achieve a partial remission, which generally last 10–15 months. Because it is at present widely felt, that combination chemotherapy has reached a plateau in its effectiveness and because of the discovery of hormone receptors, hormonotherapy is presently experiencing an unexpected revival.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cooper R: Combination chemotherapy in hormone resistant breast cancer. Proc Am Ass Cancer Res (10): 15, 1969.
Brunner K. W.: Present status of combination chemotherapy in advanced breast cancer. In: Application of Cancer Chemotherap. Antibiotics Chemother. (24): 173–188, Karger, Basel, 1978.
Canellos G. P., Pocock S. J., Taylor S. G., et al; Combination chemotherapy for metastatic breast carcinoma. Cancer (38): 1882–1886, 1976.
Tormey D., Carbone P., Band P.: Breast cancer survival in single and combination chemotherapy trials since 1968. Proc Am Ass Cancer Res (18): 64, 1977.
Broder L. E., Tormey D. C.: Combination chemotherapy of carcinoma of the breast. Cancer Treat Rev (1): 183–203, 1974.
Band P. R., Tormey D. C., Bauer M. for the ECOG: Induction chemotherapy and maintenance chemo-hormonotherapy in metastatic breast cancer. Proc Am Ass Cancer Res (18): 228, 1977.
Brunner K. W., Sonntag R. W., Martz G., Senn H. J., Obrecht P., Alberto P.: A controlled study in the. use of combined drug therapy for metastatic breast cancer. Cancer (36): 1208–1219, 1975.
Smalley R. V., Murphy S., Huguley C. M., et al: Combination versus sequential five-drug chemotherapy in metastatic breast cancer. Cancer Res (36): 3911–3916, 1976.
Chlebowski R. T., Irwin L. E., Pugh R. P., Sadoff L., et al: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res (39): 4503–4506, 1979.
De Lena M., De Palo G. M., Bonadonna G., Beretta G., Bajetta E.: Terapia del carcinoma mammario metastatizzato con ciclofosfamide, methotrexate, vincristina e fluorouracile. Tumori (59): 11–24, 1973.
Bull J. M., Tormey D. C., Li S. H., et al: A randomized trial of Adriamycin versus Methotrexate in combination drug therapy. Cancer (41): 1649–1657, 1978.
Muss H. B., White D. R., Richards F., et al: Adriamycin versus Methotrexate in five drug combination chemotherapy for advanced breast cancer. Cancer (42): 2141–2148, 1978.
Smalley R. Y., Carpenter J., Bartolucci A., et al: Comparison of cyclophosphamide, methotrexate, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer (40): 625–632, 1977.
Carom-Pereira J., Cost F. L., Henriques E.: Chemotherapy of advanced breast cancer. A randomized trial of vincristine, adriamycin and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP). Cancer (48): 1517–1521, 1981.
Brambilla C., Valagussa P., Bonadonna G.: Sequential combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol (1): 35–39, 1978.
Tormey D. C., Gelman R. B. P., Carbone P. for the ECOG: Comparison of single to alternating combination therapy in metastatic breast cancer. Am Ass Cancer Res 171 (Abstract), 1980.
Brunner K. W., Sonntag R. W., Alberto P., et al: Combined chemo- and hormonal therapy in advanced breast cancer. Cancer (39): 2923–2933, 1977.
Carter S. K.: The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Research and Treatment (1): 43–52, 1981.
Tormey DC, Falkson G, Cowley J, Falkson HC, Voelkel J and Davis TE: Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Am J Clin Oncol (5): 33–39, 1982.
Cocconi G., De Lisi V., Boni C., et al: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer (51): 581–588, 1983.
Cavalli F., Beer M., Martz G., et al: Gleichzeitige oder sequentielle hormono-chemotherapie sowie vergleich verschiedener polychemotherapien in der behandlung des metastasierenden mammakarzinoms. Schweiz Med Wschr (112): 774–783, 1982.
Cavalli F., Beer M., Martz G., Jungi W. F., Alberto P., Obrecht J. P., Mermillod B., Brunner K. W.: Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Brit Med J (1): 286, 5–8, 1983.
Legha S. S., Buzdar A. U., Smith T. L., Swenerton K. D., Hortobagyi G. N., Blumenschein G. R.: Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer (46): 438–445, 1980.
Manni A., Trujillo J. E., Pearson O. H.: Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep (64): 111–116, 1980.
Cavalli F., Pedrazzini A., Goldhirsch A., et al: Randomized trial of 3 different regimens of chemotherapy in patients receiving simultaneously hormone treatment for advanced breast cancer. Europ J Cancer and Clin Oncol (19,11): 1615–1624, 1983.
Smalley R. Y., Bartolucci A. A.: Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to 2 chemotherapy combinations. In: Mouridsen HR and Palshoff T (eds) Breast Cancer - Experimental and Clinical. Pergamon Press, 1980. pp 141–146.
Cummings F. J., Gelman R., Horton J., Caiman K.: Comparison of CMFP with CAF in patients with metastatic breast cancer. In: Proceedings 13th Int Congress UICC, Seattle, 1982. Abstract C-186.
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Cavalli, F., Goldhirsch, A., Joss, R., Brunner, K.W. (1984). Hormone-Chemotherapy in Treatment of Advanced Breast Cancer. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive